Results 61 to 70 of about 61,294 (317)

Leiomyosarcoma of the penis [PDF]

open access: yesCancer, 1972
A case of leiomyosarcoma of the penis is described. The previous reports of this tumor are summarized, and the prognosis and treatment are discussed.
N. Greenwood, H. Fox, E. C. Edwards
openaire   +3 more sources

Leiomyosarcoma of the Mesentery

open access: yesThe American Surgeon, 2022
The mesentery is a common site of metastasis from gastrointestinal, pancreatic, and biliary cancers. Primary mesenteric cancers are rare and usually mesenchymal and benign. Mesenteric leiomyosarcoma is a rare, malignant smooth muscle sarcoma with an incidence of 1:350000. It usually arises from the vasculature of the mesentery.
Martin A, Arhin, Pierre, DeMatos
openaire   +2 more sources

Case report: A case of oviductal and uterine leiomyosarcoma in an 11-year-old dog

open access: yesFrontiers in Veterinary Science, 2023
An 11-year-old, intact female Pomeranian dog was presented for evaluation due to an 18-h history of anorexia and lethargy. Abdominal ultrasound revealed a 3×3 cm mass of mixed echogenicity at the level of the left ovary.
Jillian Kazmierczak   +5 more
doaj   +1 more source

Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. [PDF]

open access: yes, 2017
Relapsed osteosarcoma is a recalcitrant tumor. A patient's cisplatinum (CDDP)-resistant relapsed osteosarcoma lung metastasis was previously established orthotopically in the distal femur of mice to establish a patient-derived orthotopic xenograft (PDOX)
Dry, Sarah M.   +23 more
core   +1 more source

Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Currently, no published data on homologous recombination deficiency (HRD) testing in the setting of molecular tumor boards exist. This study in a cohort of 237 patients encompassing 24 different tumor entities assessed by a molecular tumor board shows that inactivating alterations of BRCA1/2 are not always associated with an elevated ...
Christoph Schubart   +26 more
wiley   +1 more source

Leiomyosarcoma of the duodenum

open access: yesJournal of British Surgery, 1971
Abstract Three cases of leiomyosarcoma of the duodenum are reported. The literature is reviewed, and the clinical, diagnostic, and pathological features of this tumour are described. Wide surgical excision has proved to be the most effective treatment.
M. P. McBrien, P. E. M. Jarrett
openaire   +3 more sources

Primary leiomyosarcoma of epididymis: a case report

open access: yesJournal of Medical Case Reports
Background Leiomyosarcoma is a tumor that can develop in any organ that contains smooth muscles. Although leiomyosarcoma is common, its epididymal localization is quite rare.
Hong-Jie Chen   +4 more
doaj   +1 more source

“Pushing the margin:” utilization of renal autotransplantation to achieve complete resection in vena caval leiomyosarcomas

open access: yesJournal of Pediatric Surgery Case Reports, 2020
We report the case of a 19-year-old female who underwent resection of the sub- and infrahepatic inferior vena cava (IVC) with concomitant left kidney autotransplantation for leiomyosarcoma.
Joseph Anderson   +3 more
doaj  

Primary Leiomyosarcoma of the Ureter

open access: yesAsian Journal of Surgery, 2008
Leiomyosarcoma is a rarely seen neoplasm of the ureter, with less than 20 cases being reported in the literature to date. It is important to distinguish leiomyosarcoma from rhabdomyosarcoma, with the aid of immunohistochemical markers.
Chen Lv   +4 more
doaj   +1 more source

Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

open access: yesBritish Journal of Cancer, 2019
This subgroup analysis of a phase 3 study compares outcomes for eribulin versus dacarbazine in patients with leiomyosarcoma. Patients ≥18 years old with advanced liposarcoma or leiomyosarcoma, ECOG PS ≤2, and ≥2 prior treatment regimens were randomly ...
J. Blay   +7 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy